-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Pharma Industry News】Recently, Luye Pharma Group announced that its subsidiary Luye Pharma (Switzerland) has entered into an agreement with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis), granting the latter to Leith tomorrow.
Exclusive commercialization rights for transdermal patches in Mexico and Poland
.
Ristigmine multi-day transdermal patch is used to treat mild to moderate dementia related to Alzheimer's disease.
It is independently developed by Luye Pharma and is one of the company's core products in the field of central nervous system therapy
.
As early as September 16, 2021, Luye Pharma Group announced that its subsidiary Luye Pharma (Switzerland) has reached an agreement with ESTEVE, granting the latter the exclusive commercialization rights of the Mindoril transdermal patch in Spain
.
It is understood that with the increasing number of patients, Alzheimer's disease has become a major public health challenge worldwide
.
The development of new drugs in this disease area is challenging, and Ristigmine is currently the first-line treatment for Alzheimer's disease-related dementia and is marketed globally
.
For this cooperation, the industry expects that it will beneficially complement Exeltis' product portfolio in the field of neurological diseases
.
In addition, with ESTEVE's rich experience in the field of central nervous system diseases and a strong business operation system, it is believed that this new treatment option can be brought to local patients as soon as possible
.
In recent years, China's pharmaceutical innovation market is actually in a period of rapid development, especially after the State Drug Administration has accelerated the process of drug R&D approval, the number of domestic companies deploying innovative drugs is increasing
.
It is worth mentioning that with the continuous emergence of drug research and development results, the overseas sales of Chinese pharmaceutical companies' products have also begun to increase
.
It is reported that in recent years Bio-Tech, Henlius, and Innovent have all authorized overseas licenses to commercialize new drugs, and have seized both domestic and overseas markets
.
According to the data, in 2020, the number of Chinese medicines going overseas has reached 23, and as of August 2021, the number of overseas authorized projects has reached 13
.
From the above point of view, under the fierce competition in the domestic market, in order to develop a larger market, domestic pharmaceutical companies are targeting overseas markets one after another and authorizing products to overseas pharmaceutical companies for development
.
It is worth noting that domestic pharmaceutical companies have also played new tricks in the external authorization model
.
Recently, Tianyan Pharmaceutical (AGAD.
NS) announced that it has reached a research cooperation and exclusive technology licensing agreement with the multinational pharmaceutical company Sanofi
.
In this cooperation, Tianyan Pharmaceutical is responsible for early product development, using its safe antibody SAFEbody® technology to help Sanofi develop its new generation of monoclonal and bispecific antibodies with precise masked safety antibodies, while Sanofi will be responsible for The product will be further developed and commercialized in the future
.
Industry analysts believe that from externally authorized products to authorized technologies, it can be seen that the "gold content" of domestic pharmaceutical companies' innovation has increased significantly
.
You must know that the technology licensing model is very common overseas, but only if they have truly internationally leading technologies, other companies, especially multinational pharmaceutical companies, will spend money to introduce these technologies
.
It can be seen from the increasing frequency of product and technology authorization of domestic pharmaceutical companies that China's new drug R&D strength is gradually being recognized by overseas markets, and it no longer only depends on the "import" of innovative drugs by foreign companies; it also means that in the future, with domestic pharmaceutical companies With the continuous improvement of research and development strength, the innovative products of domestic pharmaceutical companies will gradually enter the cooperation list of large international pharmaceutical companies to achieve complementary resources and help domestic pharmaceutical companies to accelerate the development of the international market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Exclusive commercialization rights for transdermal patches in Mexico and Poland
.
Ristigmine multi-day transdermal patch is used to treat mild to moderate dementia related to Alzheimer's disease.
It is independently developed by Luye Pharma and is one of the company's core products in the field of central nervous system therapy
.
As early as September 16, 2021, Luye Pharma Group announced that its subsidiary Luye Pharma (Switzerland) has reached an agreement with ESTEVE, granting the latter the exclusive commercialization rights of the Mindoril transdermal patch in Spain
.
It is understood that with the increasing number of patients, Alzheimer's disease has become a major public health challenge worldwide
.
The development of new drugs in this disease area is challenging, and Ristigmine is currently the first-line treatment for Alzheimer's disease-related dementia and is marketed globally
.
For this cooperation, the industry expects that it will beneficially complement Exeltis' product portfolio in the field of neurological diseases
.
In addition, with ESTEVE's rich experience in the field of central nervous system diseases and a strong business operation system, it is believed that this new treatment option can be brought to local patients as soon as possible
.
In recent years, China's pharmaceutical innovation market is actually in a period of rapid development, especially after the State Drug Administration has accelerated the process of drug R&D approval, the number of domestic companies deploying innovative drugs is increasing
.
It is worth mentioning that with the continuous emergence of drug research and development results, the overseas sales of Chinese pharmaceutical companies' products have also begun to increase
.
It is reported that in recent years Bio-Tech, Henlius, and Innovent have all authorized overseas licenses to commercialize new drugs, and have seized both domestic and overseas markets
.
According to the data, in 2020, the number of Chinese medicines going overseas has reached 23, and as of August 2021, the number of overseas authorized projects has reached 13
.
From the above point of view, under the fierce competition in the domestic market, in order to develop a larger market, domestic pharmaceutical companies are targeting overseas markets one after another and authorizing products to overseas pharmaceutical companies for development
.
It is worth noting that domestic pharmaceutical companies have also played new tricks in the external authorization model
.
Recently, Tianyan Pharmaceutical (AGAD.
NS) announced that it has reached a research cooperation and exclusive technology licensing agreement with the multinational pharmaceutical company Sanofi
.
In this cooperation, Tianyan Pharmaceutical is responsible for early product development, using its safe antibody SAFEbody® technology to help Sanofi develop its new generation of monoclonal and bispecific antibodies with precise masked safety antibodies, while Sanofi will be responsible for The product will be further developed and commercialized in the future
.
Industry analysts believe that from externally authorized products to authorized technologies, it can be seen that the "gold content" of domestic pharmaceutical companies' innovation has increased significantly
.
You must know that the technology licensing model is very common overseas, but only if they have truly internationally leading technologies, other companies, especially multinational pharmaceutical companies, will spend money to introduce these technologies
.
It can be seen from the increasing frequency of product and technology authorization of domestic pharmaceutical companies that China's new drug R&D strength is gradually being recognized by overseas markets, and it no longer only depends on the "import" of innovative drugs by foreign companies; it also means that in the future, with domestic pharmaceutical companies With the continuous improvement of research and development strength, the innovative products of domestic pharmaceutical companies will gradually enter the cooperation list of large international pharmaceutical companies to achieve complementary resources and help domestic pharmaceutical companies to accelerate the development of the international market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
